UNIVERSITÄTSKLINIK FÜR HÄMATOLOGIE UND ONKOLOGIE

Publikationen

2019

  • Nimmagadda SC, Frey S, Müller P, Wolleschak D, Weinert S, Keller U, Edelmann B, Fischer T.
    SDF1a-induced chemotaxis of JAK2-V617F positive cells is dependent on Bruton's Tyrosine Kinase and its downstream targets PI3K/AKT, PLC gamma 1 and RhoA.
    Haematologica. 2019 Feb 14. [Epub ahead of print]
    Imp.-Fact.:9,09
  • Hillert LK, Bettermann-Bethge K, Nimmagadda SC, Fischer T, Naumann M, Lavrik IN.
    Targeting RIPK1 in AML cells carrying FLT3-ITD.
    Int J Cancer. 2019 Mar 3. [Epub ahead of print]
    Imp.-Fact.:7,36
  • Lowinus T, Heidel FH, Bose T, Nimmagadda SC, Schnöder T, Cammann C, Schmitz I, Seifert U, Fischer T, Schraven B, Bommhardt U.
    Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling.
    Cell Commun Signal. 2019 Jan 16;17(1):5.
    Imp.-Fact.:5,324
  • Salmanton-García J, Seidel D, Koehler P, Mellinghoff SC, Herbrecht R, Klimko N, Rácil Z, Falces-Romero I, Ingram P, Benítez-Peñuela MA, Rodríguez-Quintero J, Desoubeaux G, Barac A, Hoenigl M, Klyasova G, Puerta-Alcalde P, Cheng MP, Heinz WH, Iqba N, Krausen R, Ostermann H, Penack O, Schalk E, Sheppard DC, Willinger B, Wisplinghoff H, Vehreschild JJ, Cornely OA, Vehreschild MJGTZ, on behalf of The FungiScope® ECMM/ISHAM Working Group.
    Matched-paired analysis of patients treated for invasive mucormycosis - standard treatment vs. posaconazole new formulations (MoveOn).
    J Antimicrobial Chemother 2019; im Druck
    Imp.-Fact.:5,113
  • Schalk E, Katsounas A.
    HIV/AIDS-related refractory Kaposi sarcoma causing severe leg lymphedema.
    Open Forum Infect Dis 2019; im Druck
    Imp.-Fact.:3,371
  • Schmidt-Hieber M, Teschner D, Maschmeyer G, Schalk E.
    Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.
    Expert Rev Anti-Infect Ther 2019; im Druck
    Imp.-Fact.:3,141
  • Zeremski V, Fischer T, Schalk E.
    Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma.
    Leuk Lymphoma 2019; im Druck
    Imp.-Fact.:3,093
  • Tölle D, Hentrich M, Pelzer BW, Kremer P, Einhell S, Schulz S, Böll B, Panse J, Schmidt-Hieber M, Teschner D, Schalk E.
    Impact of neutropenia on central venous catheter-related bloodstream infections in patients with hematological malignancies at the time of central venous catheter insertion: A matched-pair analysis.
    Infect Control Hosp Epidemiol 2019;40(10):1204-1206.
    Imp.-Fact.:3,084
  • Zeremski V, Jentsch-Ullrich K, Kahl C, Mohren M, Eberhardt J, Fischer T, Schalk E.
    Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B-cell lymphoma? Results from a multicenter, retrospective study.
    Ann Hematol 2019; im Druck
    Imp.-Fact.:2,85
  • Kochanek M, Schalk E, von Bergwelt-Baildon M, Beutel G, Buchheidt D, Henze L, Hentrich M, Kiehl M, Liebregts T, von Lilienfeld-Toal M, Löhnert M, Mellinghoff S, Penack O, Piepel C, Böll B.
    Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
    Ann Hematol 2019; im Druck
    Imp.-Fact.:2,845
  • Jost F, Schalk E, Rinke K, Fischer T, Sager S.
    Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia.
    PLoS One 2019;14(7):e0204540.
    Imp.-Fact.:2,806
  • Schalk E, Zeremski V, Fischer T.
    Primary ecthyma gangraenosum due to central venous catheter-related bloodstream infection with Pseudomonas aeruginosa.
    Infection 2019;47(2):333-334
    Imp.-Fact.:2,773
  • Schalk E, Fischer T, Wolleschak D.
    Splenic cyst after abdominal trauma?
    Dtsch Arztebl Int 2019;116:362
  • Probst L, Schalk E, Liebregts T, Zeremski V, Tzalavras A, von Bergwelt-Baildon M, Hesse N, Prinz J, Vehreschild JJ, Shimabukuro-Vornhagen A, Eichenauer DA, Garcia Borrega J, Kochanek M, Böll B; Working Party on Intensive Care Medicine in Hematologic and Oncologic Patients (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
    Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study.
    . J Intensive Care 20197;7:41.

2018

  • Lipka DB, Lutsik P, Plass C.
    From Basic Knowledge to Effective Therapies
    Cancer Cell, Volume 34, Issue 6, 10 December 2018, Pages 982-995.e7
    Imp.-Fact.:22,844
  • Edelmann B, Gupta N, Schnöder T, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC , Nimmagadda SC, Müller P, Braun-Dullaeus RC, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel F, Schraven B, Isermann B, Müller AJ, Fischer T.
    JAK2-V617F promotes venous thrombosis through ß1/ß2 integrin activation
    J Clin Invest. 2018;128(10):4359-4371
    Imp.-Fact.:13,25
  • Maifrede S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik M, Huang J, Skorski T.
    Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Blood. 2018 May 21. pii: blood-2018-02-834895.[Epub ahead of print]
    Imp.-Fact.:13,164
  • Mohr J, Dash BP, Schnöder T, Wolleschak D, Herzog C, Santamaria NT, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel F
    The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function
    Leukemia, volume 32, 1211–1221 (2018)
    Imp.-Fact.:10,023
  • Nimmagadda SC, Frey S, Edelmann B, Hellmich C, Zaitseva L, König GM, Kostenis E, Bowles KM, Fischer T.
    Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
    Leukemia. 2018 Mar;32(3):846-849.
    Imp.-Fact.:10,023
  • Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.
    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
    Leukemia. 2018 Apr 17. [Epub ahead of print]
    Imp.-Fact.:10,023
  • Heinicke T, Labopin M, Schmid C, Polge E, Socié G, Blaise D, Mufti GJ, Huynh A, Brecht A, Ledoux MP, Cahn JY, Milpied N, Scheid C, Hicheri Y, Mohty M, Savani BN, Nagler A.
    Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant. 2018 Aug 6. [Epub ahead of print]
    Imp.-Fact.:4,484
  • Dash BP, Schnöder TM, Kathner C, Mohr J, Weinert S, Herzog C, Godavarthy PS, Zanetti C, Perner F, Braun-Dullaeus R, Hartleben B, Huber TB, Walz G, Naumann M, Ellis S, Vasioukhin V, Kähne T, Krause DS, Heidel FH.
    Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells.
    J Cancer Res Clin Oncol. 2018 Aug 6. [Epub ahead of print]
    Imp.-Fact.:3,282
  • Marhäll A, Heidel F, Fischer T, Rönnstrand L.
    Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Ann Hematol. 2018 May;97(5):773-780.
    Imp.-Fact.:3,083
  • Kiehl MG, Beutel B, Böll B, Buchheidt D, Forkert R, Fuhrmann V, Knöbl P, Kochanek M, Kroschinsky F, La Rosée P, Liebregts T, Lück C, Olgemoeller U, Schalk E, Shimabukuro-Vornhagen A, Sperr WR, Staudinger T, von Bergwelt Baildon M, Wohlfarth P, Zeremski V, Schellongowski P
    Consensus statement for cancer patients requiring intensive care support.
    Ann Hematol 2018 Jul;97(7):1271-1282
    Imp.-Fact.:3,083
  • Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild MJGT for the AGIHO Working Group.
    Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
    Ann Hematol January 2018, Volume 97, Issue 1, pp 31–49
    Imp.-Fact.:3,083
  • Mellinghoff SC, Bassetti M, Dörfel D, Hagel S, Lehners N, Plis A, Schalk E, Vena A, Cornely OA
    Isavuconazole shortens the QTc interval
    2018 Apr;61(4):256-260. Epub 2018 Jan 3.
    Imp.-Fact.:2,252
  • Lilienthal P, Tetschke M, Pottgiesser T, Fischer T, Schalk E, Sager S.
    Mathematical Modeling of RBC count dynamics after blood loss.
    Processes 2018;6(9):157
    Imp.-Fact.:1,279
  • Schmidt-Hieber M, Teschner D, Schalk E.
    Febrile Neutropenie – Risikofaktoren, Prophylaxe und Algorithmen zur antimikrobiellen Therapie.
    Journal Onkologie 2018;5:25-33
  • Fischer T.
    Das internistische Jahr 2017 - die wichtigsten Fortschritte und Entwicklungen
    Ärzteblatt Sachsen-Anhalt. Bd. 29.2018, 4, S. 17-20;

2017

  • Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B.
    Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.
    Nat Commun. 2017 Aug 21;8(1):311.
    Imp.-Fact.:12,124
  • Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D.
    Gain of function in Jak2V617F-positive T-cells.
    Leukemia. 2017 Apr;31(4):1000-1003.
    Imp.-Fact.:10,023
  • Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H; and for the German-Austrian AMLSG.
    Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
    Leukemia. 2017 May;31(5):1217-1220.
    Imp.-Fact.:10,023
  • Einsele H, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C.
    Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.
    Leukemia. 2017 Jun;31(6):1463-1466.
    Imp.-Fact.:10,023
  • Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH, Fischer T.
    JAK2-V617F activates ß1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1.
    Leukemia. 2017 May;31(5):1223-1226. Epub 2017 Jan 18
    Imp.-Fact.:10,023
  • Reichenbach F, Wiedenmann C, Schalk E, Becker D, Funk K, Scholz-Kreisel P, Todt F, Wolleschak D, Dohner K, Marquardt JU, Heidel F, Edlich F.
    Mitochondrial BAX determines the predisposition to apoptosis in human AML.
    Clin Cancer Res 2017; im Druck
    Imp.-Fact.:9,619
  • Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, Handschuh J, Braun-Dullaeus RC, Schrappe M, Lindquist JA, Mertens PR, Thomas U, Brunner-Weinzierl MC.
    RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.
    Cell Death Differ. 2017 Feb;24(2):371-383. Epub 2016 Dec 23.
    Imp.-Fact.:8,339
  • Arra A, Lingel H, Kuropka B, Pick J, Schnoeder T, Fischer T, Freund C, Pierau M, Brunner-Weinzierl MC.
    The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.
    Oncoimmunology. 2017 Jan 20;6(2):e1273300
    Imp.-Fact.:7,719
  • Schalk E, Zeremski V, Fischer T.
    Impact of lymphopenia on prognosis of patients with primary central nervous system lymphoma.
    Eur J Cancer. 2017 Apr;75:280-283.
    Imp.-Fact.:6,029
  • Einsele H, Engelhardt M, Tapprich C, Müller J, Liebisch P, Langer C, Kropff M, Mügge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA, Salwender H, Hebart H, Straka C, Knop S.
    Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
    Br J Haematol. 2017 Nov;179(4):586-597.
    Imp.-Fact.:5,67
  • Bongartz H, Hessenkemper W, Müller C, Fensky M, Fritsch J, Mandel K, Behrmann I, Haan C, Fischer T, Feller SM, Schaper F.
    The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
    Cell Signal. 2017 Jul;35:37-47.
    Imp.-Fact.:3,937
  • Schalk E, Biehl LM, Färber J, Schlüter D, Vehreschild MJGT, Fischer T.
    Determination of a cut-off time-point for prophylactic exchange of central venous catheters for prevention of central venous catheters-related bloodstream infections in patients with hematological malignancies.
    Infect Control Hosp Epidemiol 2017; 38(7):888-889
    Imp.-Fact.:3,55
  • Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH.
    Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
    J Cancer Res Clin Oncol. 2017 May;143(5):807-820.
    Imp.-Fact.:3,503
  • Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih HR, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs HG, Horst HA, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik VI, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group (AMLSG).
    Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
    Ann Hematol. 2017 Dec;96(12):1993-2003.
    Imp.-Fact.:3,083
  • Harrison, Claire N. Koschmieder, Steffen, Foltz, Lynda; Guglielmelli, Paola; Flindt, Tina; Koehler, Michael; Mathias, Jonathan; Komatsu, Norio; Boothroyd, Robert N.; Spierer, Amber; Ronco, Julian Perez; Taylor-Stokes, Gavin; Waller, John; Mesa, Ruben A.
    The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
    Annals of hematology. Oct 2017, Volume 96, Issue 10, pp 1653–1665
    Imp.-Fact.:3,083
  • Koehler M, · Hornemann B, ·Holzner B, Schäffeler N, Zimmermann T, · Nest A, · Wifling K, ·Herschbach P.
    Zukunft jetzt – Implementierung eines IT-gestützten Distress- Screenings (Expertenbasierte Konsensempfehlungen zum Einsatz in der onkologischen Routineversorgung)
    Onkologe. Epub 2017 Apr 10.
    Imp.-Fact.:0,09
  • Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
    Das CARE-for-CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung
    Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2017;32(06):479-484.
  • Quidde J, Koch B, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A.
    Versorgung von Patienten nach Krebserkrankung im Kindes-, Jugend- oder jungen Erwachsenenalter
    J Onkol - Z Onkol Fortb. 2017;2017(10):862-866.

2016

  • Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M.
    Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
    Lancet. 2016 Jun 13. pii: S0140-6736(16)00739-X. [Epub ahead of print]
    Imp.-Fact.:44,002
  • Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.
    Lipka DB, Wagner MC, Dziadosz M, Fischer T.
    Leukemia. 2016 May 24.
    Imp.-Fact.:12,104
  • Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K.
    Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
    Leukemia. 2016 Oct 24, [Epub ahead of print].
    Imp.-Fact.:12,104
  • Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD.
    NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD positive AML cells.
    Leukemia. 2016 Feb;30(2):473-83. Epub 2015 Aug 26.
    Imp.-Fact.:11,702
  • Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH.
    Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.
    Leukemia. 2016 Apr;30(4):991-5.
    Imp.-Fact.:11,702
  • Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong S, Döhner K, Fischer T, Heidel FH.
    Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
    Leukemia. 2016 May;30(5):1220-5.
    Imp.-Fact.:11,702
  • Wolleschak, D, Heidel, FH.
    Chronic myelogenous leukemia evolving after treatment of multiple myeloma.
    Blood 2016; 128(1),146
    Imp.-Fact.:10,131
  • Lipka DB, Wagner MC, Dziadosz M, Fischer T.
    Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.
    Leukemia. 2016 Oct;30(10):2090-2093.
    Imp.-Fact.:10,023
  • Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O, Christopeit M, Buchheidt D, Meyding-Lamadé U, Hähnel S, Wolf HH, Ruhnke M, Schwartz S, Maschmeyer G.
    CNS infections in patients with hematological disorders (including allogeneic stem cell transplantation) – Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).
    Ann Oncol. 2016 Jul;27(7):1207-25
    Imp.-Fact.:7,04
  • von Lilienfeld-Toal M, Berger A, Christopeit M, Hentrich M, Heussel CP, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf HH, Lehners N, Schalk E, Mayer K.
    Community acquired respiratory virus (CRV) infections in cancer patients - guidelines on diagnosis and management by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Eur J Cancer 2016;67:200-212
    Imp.-Fact.:6,163
  • Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T, Heidel FH.
    Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo
    Haematologica. 2016 Mar;101(3):e81-5.
    Imp.-Fact.:5,814
  • Schalk E, Fischer T.
    Biased low incidence of central venous catheter-related bloodstream infections in controlled clinical trials?
    Infect Control Hosp Epidemiol. 2016 May;37(5):617-9
    Imp.-Fact.:4,175
  • Hermann B, Lehners N, Brodhun M, Boden K, Hochhaus A, Kochanek M, Meckel K, Mayer K, Rachow T, Rieger C, Schalk E, Weber T, Schmeier-Jürchott A, Schlattmann P, Teschner D, von Lilienfeld-Toal M.
    Influenza virus infections in patients with malignancies - characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).
    . Eur J Clin Microbiol Infect Dis 2017;36(3):565-573
    Imp.-Fact.:4,097
  • Koehler P, Hamprecht A, Adam T, Bader O, Becker C, Bekerdijan-Ding I, Buchheidt D, Doelken G, Elias J, Haase G, Hahn-Ast C, Karthaus M, Kekulé A, Krause S, Neumann S, Keller P, Kiehl M, Rohde H, La Rosée P, Ruhnke M, Schalk E, Schafhausen P, Schwartz S, Vergoulidou M, Silling G, Schulz K, Staib P, Ullmann A, Weber T, Cornely OA, Vehreschild MJGT.
    Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukemia - the SEPIA study.
    Int J Antimicrob Agents 2017; 49(2):218-223
    Imp.-Fact.:4,097
  • Sasse S, Alram M, Müller H, Smardová L, Metzner B, Doehner H, Fischer T, Niederwieser DW, Schmitz N, Schäfer-Eckart K, Raemaekers JM, Schmalz O, Tresckow BV, Engert A, Borchmann P.
    Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
    Leuk Lymphoma. 2016 May;57(5):1067-73.
    Imp.-Fact.:3,093
  • Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH.
    Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.
    J Cancer Res Clin Oncol 2016;142(9):2041-9
    Imp.-Fact.:3,081
  • Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D.
    Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).
    J Cancer Res Clin Oncol. 2016 Jan;142(1):305-15.
    Imp.-Fact.:3,081
  • Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.
    Leukemogenic potency of the novel FLT3-N676K mutant.
    Ann Hematol. 2016 Apr;95(5):783-91.
    Imp.-Fact.:2,634
  • Zeremski V, Koehler M, Fischer T, Schalk E.
    Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial.
    Ann Hematol (2016) 95:793–799
    Imp.-Fact.:2,634
  • Schmidt H, Merkel D, Koehler M, Flechtner HH, Sigle J, Klinge B, Jordan K, Vordermark D, Landenberger M, Jahn P.
    PRO-ONKO-selection of patient-reported outcome assessments for the clinical use in cancer patients-a mixed-method multicenter cross-sectional exploratory study.
    Support Care Cancer. 2016 Jun;24(6):2503-12
    Imp.-Fact.:2,364
  • Schalk E, Heidel FH.
    Leukemic mastopathy.
    Int J Hematol. 2016 Apr;103(4):357-8.
    Imp.-Fact.:1,918
  • Mohren M, Jentsch-Ullrich K, Koenigsmann M, Kropf S, Schalk E, Lutze G.
    High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.
    Int J Hematol. 2016 Feb;103(2):189-95.
    Imp.-Fact.:1,918
  • Perner F, Schnöder TM, Fischer T, Heidel FH.
    Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML.
    Anticancer Res. 2016 Dec;36(12):6249-6258.
    Imp.-Fact.:1,826
  • Zeremski V, Mawrin C, Fischer T, Schalk E.
    Diagnostic and therapeutic challenges in extragonadal yolk sac tumor with hepatoid differentiation: A case report.
    Mol Clin Oncol 2016; ;6(1):79-82
    Imp.-Fact.:1,5
  • Zeremski V, Savic A, Ilic T, Milosevic I, Maksimovic M, Vuckovic B.
    A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept.
    Srp Arh Celok Lek. 2016 Jan-Feb;144(1-2):81-4.
    Imp.-Fact.:0,277
  • Jost F, Rinke K, Fischer T, Schalk E, Sager S.
    Optimum experimental design for patient specific mathematical leukopenia models.
    IFAC-PapersOnLine 2016;49(26):344-349.
  • Schmidt-Hieber M, Christopeit M, Schalk E.
    Infektionen bei Patienten mit hämatologisch-onkologischen Erkrankungen.
    Notfall Rettungsmed 2017;20(3):206-215
  • Köhler M, Hoppe S.
    Psychoonkologische Spezialsprechstunde für Eltern junger Krebspatienten
    Info Onkologie 07/2016
  • Rinke K, Jost F, Findeisen R, Fischer T, Bartsch R. Schalk E, Sager, S
    Parameter estimation for leukocyte dynamics after chemotherapy
    IFAC-PapersOnLine - Frankfurt: Elsevier, Bd. 49.2016, 26, S. 44-49
  • Schalk E, Fischer T.
    Hemophagocytic lymphohistiocytosis as an unusual cause of prolonged bicytopenia after chemotherapy.
    Clin Case Rep 2016;4(10):1017-1018

2015

  • Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A.
    Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Lancet 2015 Apr; 385 (9976):1418–1427
    Imp.-Fact.:39,207
  • Koehler M, Fischer T.
    How health-related quality-of-life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making.
    Journal of Clinical Oncology, Early Release Feb 23,2015
    Imp.-Fact.:17,96
  • Madhusudhan T, Wang H, Dong W, Ghosh S, Bock F, Thangapandi VR, Ranjan S, Wolter J, Kohli S, Shahzad K, Heidel F, Krueger M, Schwenger V, Moeller MJ, Kalinski T, Reiser J, Chavakis T, Isermann B.
    Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy.
    Nat Commun. 2015 Mar 10;6:6496.
    Imp.-Fact.:10,742
  • Heidel FH, Arreba-Tutusaus P, Armstrong SA, Fischer T.
    Evolutionarily conserved signaling pathways: Acting in the shadows of Acute Myelogenous Leukamia’s genetic diversity.
    Clinical Cancer Research 2014, 2015 Jan 15;21(2):240-248.
    Imp.-Fact.:8,193
  • Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators.
    A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
    Haematologica. 2015 Sep;100(9):1139-45. Epub 2015 Jun 11.
    Imp.-Fact.:5,814
  • Richter D, Koehler M, Friedrich M, Hilgendorf I, Mehnert A, Weißflog G.
    Psychosocial interventions for adolescents and young adult cancer patients: A systematic review and meta-analysis.
    Crit. Rev. Oncol./Hematol. ; in press
    Imp.-Fact.:4,046
  • Scheinpflug K, Schalk E, Grabert E, Achenbach HJ.
    Procalcitonin is not useful to discriminate between infectious and non-infectious CRP elevation in patients with non-small cell lung cancer.
    Infect Contol Hosp Epidemiol 2015 Sep;36(9):1117-8
    Imp.-Fact.:4,02
  • Schalk E, Färber J, Fischer T, Heidel FH.
    Central venous catheter-related bloodstream infections in obese hematologic patients.
    Infect Control Hosp Epidemiol 2015;2015 Aug;36(8):995-6
    Imp.-Fact.:4,02
  • Schalk E, Hanus L, Färber J, Fischer T, Heidel FH.
    Prediction of central venous catheter-related bloodstream infections (CRBSI) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS).
    Ann Hematol. 2015 Sep;94(9):1451-6
    Imp.-Fact.:2,634
  • Köhler M .
    Adoleszente und junge Erwachsene mit Krebs
    Onkologe 2015 Online
    Imp.-Fact.:0,09
  • Schalk E, Garlipp B. , Bruns CJ, Fischer T.
    Weichtteiltumoren- Allgemein-klinische Aspekte – chirurgische und medikamentöse Therapie
    Onkologe 2015
    Imp.-Fact.:0,09
  • Koehler M, Hoppe S, Frommer J, Flechtner HH, Kropf S, Fischer T.
    AYA-PARENTS 2012: Randomisierte klinische Studie zu einer strukturierten Kurzintervention für Eltern Adoleszenter und junger Erwachsener (AYA) mit malignen hämatologischen Erkrankungen.
    Forum DKG 2015;30(6):538-39.

2014

  • Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW.
    Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy.
    Cell Stem Cell. 2014 Dec 4;15(6):775-90.
    Imp.-Fact.:22,151
  • Wolleschak D, Heidel FH.
    A rare cause of lower back pain.
    Blood 124: 165
    Imp.-Fact.:9,898
  • Neumann J, Riek-Burchardt M, Herz J, Doeppner TR, König R, Hütten H, Etemire E, Männ L, Klingberg A, Fischer T, Görtler MW, Heinze HJ, Reichardt P, Schraven B, Hermann DM, Reymann KG, Gunzer M.
    Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke.
    Acta Neuropathol. 2014 Nov 13.
    Imp.-Fact.:9,777
  • Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE,Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S.
    Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
    Blood 2014-02-558114 (ahead of print April 24, 2014)
    Imp.-Fact.:9,06
  • Schnöder TM, Arreba-Tutusaus P, Griehl I, Bullinger L, Buschbeck M, Lane SW, Döhner K, Plass C, Lipka DB, Heidel FH, Fischer T
    Epo-Induced Erythroid Maturation Is Dependent on Plc gamma 1 Signaling.
    Cell Death Differ. 2014 Nov 14,. [Epub ahead of print]
    Imp.-Fact.:8,385
  • Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt B, Ruhnke M, Penack O, Salwender H, Wolf H, Christopeit M, Neumann, Maschmeyer M, Karthaus M.
    Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology.
    Annals of Oncology 25: 936–947, 2014
    Imp.-Fact.:7,384
  • Wolleschak D, Mack TS, Perner F, Frey S, Schnoeder TM, Wagner MC, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH.
    Clinically relevant doses of FLT3-kinase inhibitors Quizartinib and Midostaurin do not impair T-cell reactivity and function
    Haematologica. 2014 Mar 14. [Epub ahead of print]
    Imp.-Fact.:5,935
  • Benderska N, Ivanovska J, Rau TT, Schulze-Luehrmann J, Mohan S, Chakilam S, Gandesiri M, Ziesché E, Fischer T, Söder S, Agaimy A, Distel L, Sticht H, Mahadevan V, Schneider-Stock R.
    DAPK-HSF1 interaction as a new positive feedback loop for TNF-induced apoptosis in colorectal cancer cells.
    J Cell Sci. 2014 Nov 6. pii: jcs.157024. [Epub ahead of print]
    Imp.-Fact.:5,325
  • Roeyen CR, Scurt FG, Brandt S, Kuhl VA, Martinkus S, Djudjaj S, Raffetseder U, Royer HD, Stefanidis I, Dunn SE, Dooley S, Weng H, Fischer T, Lindquist JA, Mertens PR.
    Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities.
    Cell Commun Signal. 2013 Aug 27;11:63.
    Imp.-Fact.:4,67
  • Schalk E, Tammer I, Heidel FH.
    Germ and hematology - underlying disease in-fluences diversity of germ spectra and antibiotic therapy.
    Infect Control Hosp Epidemiol. 2014 Feb;35(2):208-10.
    Imp.-Fact.:4,02
  • Schalk E, Färber J, Fischer T.
    Multidrug-resistant Gram-negative bacteria (MRGN) in hematology and oncology.
    Infect Control Hosp Epidemiol 2014: Vol. 35, No. 9 (September 2014), pp. 1203-1204
    Imp.-Fact.:4,02
  • Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J, Jarosinska RJ, Schmid C, Finke J, Stevens WB, Schouten HC, Kaufmann M, Sebban C, Trneny M, Kobbe G, Fornecker LM, Schetelig J, Kanfer E, Heinicke T, Pfreundschuh M, Diez-Martin JL, Bordessoule D, Robinson S, Dreger P.
    Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
    Ann Oncol. 2014 May;25(5):1053-8
    Imp.-Fact.:2,866
  • Köhler M, Fischer T, Kropf S, Frommer J.
    Quantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events: the somatic burden score.
    Supportive Care in Cancer 2014 [EPUB ahead of print]
    Imp.-Fact.:2,649
  • Krüger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, Maschmeyer G, Niederwieser D, Dölken G.
    Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)
    Ann Hematol. 2014 Sep;93(9):1587-97, Epub 2014 Apr 30
    Imp.-Fact.:2,634
  • Penack O, Becker C, Buchheidt B, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H.
    Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).
    Ann Hematol (2014) 93:1083–1095
    Imp.-Fact.:2,634
  • Heinicke T, Hütten H, Kalinski T, Franke I, Bonnekoh B, Fischer T.
    Sustained remission of blastic plasmacytoid dendritic cell neoplasm after unrelated allogeneic stem cell transplantation-a single center experience.
    Ann Hematol. 2014 Aug 21 [Epub ahead of print]
    Imp.-Fact.:2,634
  • Schalk E, Geginat G, Schulz, C, Schlüter D, Fischer T.
    The incidence of norovirus infections in cancer patients shows less seasonal variability compared to patients with other diseases.
    Ann Hematol (2014) 93:889–890.
    Imp.-Fact.:2,634

2013

  • Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE.
    Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial.
    J Clin Oncol. 2013 Jul 29. [Epub ahead of print]
    Imp.-Fact.:18,038
  • Heidel FH , Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Dohner K, Vasioukhin V, Fischer T, Armstrong S.
    The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.
    Journal of Experimental Medicine, 2013 Jan 14;210(1):15-22
    Imp.-Fact.:13,853
  • Wagner MC, Dziadosz M, Melo JV, Heidel FH, Fischer T, Lipka DB.
    Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells.
    Leukemia. Bd. 27.2013, 7, S. 1567-1570;
    Imp.-Fact.:10,164
  • Mullally A, Bruedigam C, Poveromo L, Heidel F, Purdon A, Vu T, Austin R, Heckl D, Breyfogle L, Kuhn CP, Kalaitzidis D, Armstrong S, Williams D, Hill G, Ebert B, Lane S.
    Depletion of Jak2V617F MPN-propagating stem cells by interferon-alpha in a murine model of polycythemia vera.
    Blood 2013.May 2;121(18):3692-702
    Imp.-Fact.:9,898
  • Caldarelli A, Müller JP, Paskowski-Rogacz M, Herrmann K, Bauer R, Koch S, Henninger AK, Krastev D, Ding L, Kasper S, Fischer T, Brodhun M, Böhmer FD, Buchholz F.
    A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling.
    Leukemia. 2013 Mar 19. [Epub ahead of print]
    Imp.-Fact.:9,561
  • Deangelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG.
    Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    Leukemia. 2013, 27, 1628–1636
    Imp.-Fact.:9,561
  • Vehreschild MJGT, Vehreschild JJ, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M, Maschmeyer G, Schalk E, Cornely OA, Neumann S.
    Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
    Ann Oncol 2013;24:1189-1202.
    Imp.-Fact.:6,425
  • Wolleschak D, Schalk E, Krogel C, Schnoeder TM, Luehr H, Jentsch-Ullrich K, Fischer T, Heidel FH.
    Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.
    Hematol Oncol. 2013 Jun 11;6(1):39.
    Imp.-Fact.:4,458
  • Ivanovska J, Tregubova A, Mahadevan V, Chakilam S, Gandesiri M, Benderska N, Ettle B, Hartmann A, Söder S, Ziesché E, Fischer T, Lautscham L, Fabry B, Segerer G, Gohla A, Schneider-Stock R.
    Identification of DAPK as a scaffold protein for the LIMK/cofilin complex in TNF-induced apoptosis.
    Int J Biochem Cell Biol. 2013 Aug;45(8):1720-9
    Imp.-Fact.:4,152
  • Koehler M, Fischer T, Frommer J.
    Caught by an acute leukaemia: facing patients’ own experiences.
    Leukemia Research 37 (2013) 481– 482
    Imp.-Fact.:2,472
  • Schmitt F, Nguyen PH, Gupta N, Mayer D.
    Eph receptor B4 is a regulator of estrogen receptor alpha in breast cancer cells
    Journal of receptors and signal transduction.Bd. 33.2013, 4, S. 244-248
    Imp.-Fact.:1,63
  • Schalk E, Wolleschak D, Fischer T.
    Maligne Lymphome - Diagnostik und Therapie
    Tumorzentrum aktuell Bd. 10.2013, 1, S. 24-28

2012

  • Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA.
    Genetic and Pharmacologic Inhibition of beta-Catenin Targets Imatinib Resistant Leukemia Stem Cells in CML.
    Cell Stem Cell 2012 Apr 6;10(4):412-24
    Imp.-Fact.:25,943
  • Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, Deangelo DJ, Huntsman-Labed A, Dutreix C, Del Corral A, Giles F.
    Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
    Leukemia. 2012 Apr 27 [Epub ahead of print]
    Imp.-Fact.:9,561
  • Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, Linn YC, Kröger M, Reiter A, Salih HR, Heinicke T, Stuhlmann R, Müller L, Giagounidis A, Meyer RG, Brugger W, Vöhringer M, Dreger P, Mori M, Basara N, Schäfer-Eckart K, Schultheis B, Baldus C, Neubauer A, Burchert A.
    High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
    Leukemia. 2012 Apr 16. doi: 10.1038/leu.2012.105. [Epub ahead of print]
    Imp.-Fact.:9,561
  • Korfel A, Weller M, Martus P, Roth P, Klasen HA, Roeth A, Rauch M, Hertenstein B, Fischer T, Hundsberger T, Leithäuser M, Birnbaum T, Kirchen H, Mergenthaler HG, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Fischer L
    Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL) - experience from the G-PCNSL-SG1 trial
    Annals of oncology. - Oxford: Oxford Univ. Press, Bd. 23.2012, 9, S. 2374-2380
    Imp.-Fact.:6,425
  • Arora D, Köthe S, van den Eijnden M, van Huijsduijnen R H, Heidel F , Fischer T, Scholl S, Toelle B, Böhmer S-A, Lennartsson J, Isken F, Müller-Tidow C, Böhmer F-D.
    Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression.
    Cell Communication and Signaling; 2012 Jul 12
    Imp.-Fact.:5,5
  • Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Hochhaus A, Fischer T, Scholl S.
    Ponatinib can overcome resistance of FLT3-ITD harbouring additional point mutations including the previously refractory F691I mutation
    Br J Haematol. 2012 May;157(4):483-92
    Imp.-Fact.:4,942
  • Lipka DB, Wagner M-C, Dziadosz M, Schnöder T, Heidel F, Schemionek M, Melo JV, Kindler T, Müller-Tidow C, Koschmieder S, Fischer T.
    Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells.
    PLoS One 2012 Jul 16
    Imp.-Fact.:4,092
  • Heidel FH, Mack TS, Razumovskaya E, Blum MC, Lipka DB, Ballaschk A, Kramb J-P, Plutizki S, Rönnstrand L, Dannhardt G, Fischer T.
    3,4-Diarylmaleimides—a novel class of kinase inhibitors—effectively induce apoptosis in FLT3-ITD-dependent cells
    Ann Hematol (2012) 91:331–344
    Imp.-Fact.:2,919
  • Müller C, Gardemann A, Keilhoff G, Peter D, Wiswedel I, Schild L
    Prevention of free fatty acid-induced lipid accumulation, oxidative stress, and cell death in primary hepatocyte cultures by a Gynostemma pentaphyllum extract.
    Phytomedicine. 2012 Mar 15;19(5):395-401
    Imp.-Fact.:2,662
  • Dziadosz M, Wagner M-C, Lipka DB, Fischer T, Bartels H.
    High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal standard.
    Journal of Liquid Chromatography & Related Technologies 2012.35(17):2503-2510
    Imp.-Fact.:0,706
  • Heine V, Schuetze F, Koehler M, Frommer J.
    From life-threatening experiences to ideas of rescue: coping with trajectories of suffering.
    Research in Psychotherapy: Psychopathology, Process and Outcome (online-Journal) ) 2012, Vol. 15, No. 2, 107–116
  • Kasper S, Breitenbuecher F, Heidel F, Hoffarth S, Markova B, Schuler M, Fischer T.
    Targeting MCL-1 sensitizes FLT3-ITD positive leukemias to cytotoxic therapies
    Blood Cancer Journal 2012 Mar 09
  • Köhler M, Frommer J, Flechtner HH, Kropf S, Fischer T.
    Strukturierte psychoonkologische Kurzintervention für Eltern Adoleszenter und junger Erwachsener (AYA) mit malignen hämatologischen Erkrankungen: eine randomisierte klinische Studie.
    Tumorzentrum aktuell 01/2012;30-35.
  • Lange T, Kiefer T, Junghanss C, Wickenhauser C, Ernst T, Heidel F.
    Myeloproliferative Neoplasien
    Best Practice Onkologie 2012 5(7):34-44
  • Heidel, FH, Fischer, T.
    Chronische myeloische Leukaemie
    Rationelle Diagnostik und Therapie in der Inneren Medizin. 2012, 8a
  • Wolleschak D, Fischer T, Heidel FH.
    Aktuelle und neue Therapieoptionen bei myeloproliferativen Erkrankungen
    Tumorzentrum aktuell 01/2012;22-29.

2011

  • Fischer T
    Rethinking bioactivity of FLT3 inhibitors
    Blood 2011 Mar 24;117(12):3247-8.
    Imp.-Fact.:10,555
  • Koehler K, Dogan E, Koehler M, Heine V, Frommer J.
    Surviving the initial phase: Subjective theories of illness of patients suffering from acute leukaemia at the end of first in-patient treatment.
    Z Psychosom Med Psychother. 2011; 2:141-56
    Imp.-Fact.:1,689
  • Koehler M, Koehler K, Koenigsmann M, Kreutzmann N, Fischer, T, Frommer J
    Beyond diagnosis: subjective theories of illness in adult patients with acute myeloid leukemia
    Hematology. 2011 Jan;16(1):5-13.
    Imp.-Fact.:1,333
  • Heidel FH, Mar BG, Armstrong, SA.
    Self-renewal related signaling in myeloid leukemia stem cells
    Int J Hematol. 2011 Aug;94(2):109-17. Epub 2011 Jul 29.
    Imp.-Fact.:1,324

2010

  • Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A.
    Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma
    J Clin Oncol. 2010 Dec 1;28(34):5074-80. Epub 2010 Oct 25.
    Imp.-Fact.:17,793
  • Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ.
    A Phase IIB Trial of Oral Midostaurin (PKC412), the FLT3 and Multi-targeted Kinase Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (MDS) with Either Wild-Type or Mutated-FLT3.
    J Clin Oncol. 2010 Oct 1;28(28):4339-45. Epub 2010 Aug 23.
    Imp.-Fact.:17,793
  • Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M.
    High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1) - a phase 3, randomised, non-inferiority trial
    Lancet Oncol. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20.
    Imp.-Fact.:14,47
  • Kindler T, Lipka DB, Fischer T.
    FLT3 as a therapeutic target in AML: still challenging after all these years
    Blood. 2010 Dec 9;116(24):5089-102. Epub 2010 Aug 12.
    Imp.-Fact.:10,555
  • Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Dünzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM.
    Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
    Leukemia. 2010 Jul;24(7):1299-301. Epub 2010 Jun 3.
    Imp.-Fact.:8,296
  • González-Carmona MA, Vogt A, Heinicke T, Quasdorff M, Hoffmann P, Yildiz Y, Schneider C, Serwe M, Bartenschlager R, Sauerbruch T, Caselmann WH.
    Inhibition of hepatitis C virus gene expression by adenoviral vectors encoding antisense RNA in vitro and in vivo.
    J Hepatol. 2010 Nov 30. [Epub ahead of print]
    Imp.-Fact.:7,818
  • Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T.
    Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma driven activation of mTOR/p70S6-kinase pathway.
    Oncogene. 2010 Feb 4;29(5):739-51. Epub 2009 Nov 2.
    Imp.-Fact.:7,135
  • Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M.
    Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Int J Cancer. 2010 Sep 1;127(5):1197-208.
    Imp.-Fact.:4,734
  • Schalk E, Bohr URM,König B, Scheinpflug K, Mohren M.
    Clostridium difficile-associated diarrhoea, a frequent compliction in patients with acute myeloid leukaemia.
    Ann Hematol 2010;89:9-14
    Imp.-Fact.:2,919
  • Krogel C, Fischer T, Heidel F.
    Severe Paraneoplastic Pemphigus in a Patient With Follicular Lymphoma
    Eur J Haematol. 2010 Apr;84(4):365. Epub 2009 Oct 21.
    Imp.-Fact.:2,345
  • Bölter AF, Lange J, Anger B, Olbricht S, Koehler M, Frommer J.
    Who has more anxiety concerning a shortened life span: terminal cancer patients or those in curative therapy?
    Psychother Psych Med: 60;7, 255-261
    Imp.-Fact.:0,904
  • Bölter, Annette F.; Lange, Julia; Anger, Bernd; Olbricht, Sigrid; Köhler, Michael; Frommer, Jörg.
    Wer hat größere Furcht vor einer Verkürzung der Lebensspanne: palliativ oder kurativ behandelte Krebspatienten?
    Psychother Psych Med 2010; 60: 255-261
    Imp.-Fact.:0,904
  • Rüsseler, A.V.; Brors, B.; Fischer, Thomas; Hartmann, J.T.; Hartmann, W.; Hohenberger, P.; Lichter, P.; Marx, A.; Mechtersheimer, G.; Penzel, R.; Renner, M.; Schildhaus, H.-U.; Schirmacher, P.; Sievers, E.; Ströbel, P.; Wardelmann, E.; Ziesché, E.; Büttner, R.
    Molekularpathologie von Sarkomen, Erste Ergebnisse des Sarkomforschungsverbundes KoSar
    Pathologe 2010 · [Suppl 2] 31:211–214
    Imp.-Fact.:0,414
  • Müller C, Gardemann A, Keilhoff G, Peter D, Wiswedel I, Kropf S, Schild L
    Palmitate protects hepatocytes from oxidative stress and triacylglyceride accumulation by stimulation of nitric oxide synthesis in the presence of high glucose and insulin concentration.
    Free Radic Res. 2010 Dec;44(12):1425-34

2009

  • Kayser S, Schlenk RF, Correa Londono M, Breitenbuecher F, Wittke K, Du J, Groner S, Spath D, Krauter J, Ganser A, Dohner H, Fischer T, Dohner K.
    Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.
    Blood. 2009 Sep 17;114(12):2386-92. Epub 2009 Jul 14
    Imp.-Fact.:10,555
  • Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, Duyster J, Haferlach T, Huber C, Fischer T.
    Identification of a Novel Type of ITD Mutations Located in Non-Juxtamembrane Domains of the FLT3 Tyrosine Kinase Receptor.
    Blood 2009 Apr 23;113(17):4074-7. Epub 2008 May 15.
    Imp.-Fact.:10,555
  • Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Kindler T, Böhmer F, Huber C, Fischer T.
    A Novel Molecular Mechanism of Primary Resistance to FLT3-Kinase Inhibitors in Acute Myeloid Leukaemia.
    Blood 2009 Apr 23;113(17):4063-73. Epub 2009 Jan 14.
    Imp.-Fact.:10,555
  • Koehler M, Koenigsmann M, Frommer J.
    Coping with illness and subjective theories of illness in adult patients with haematological malignancies: Systematic review.
    Crit Rev Oncol/Hematol 2009; 69, 237-257
    Imp.-Fact.:4,632
  • Dickinson M, Ritchie D, Deangelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM.
    Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
    2009 Oct;147(1):97-101. Epub 2009 Aug 5.
    Imp.-Fact.:4,597
  • Heidel F, Lipka D B, Mirea F K, Mahboobi S, Grundler R, Kancha R K, Duyster J, Naumann M, Huber C , Böhmer F D, Fischer T.
    Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
    Br J Haematol. 2009 Mar;144(6):865-874. Epub 2009 Jan 16.
    Imp.-Fact.:4,49
  • Schalk E, Neum S, Kranz S, Scheinpflug K, Mohren M .
    Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib.
    Leuk Res 2009;33(3):e6-e7.
    Imp.-Fact.:2,561
  • Schalk E, Krogel C, Scheinpflug K, Mohren M.
    Lymphomatoid granulomatosis in a patient with rheumatoid arthritis receiving methotrexate: successful treatment with the anti-CD20 antibody mabthera.
    Onkologie 2009;32:440-441
    Imp.-Fact.:1,545
  • Kreft A, Springer E, Lipka DB, Kirkpatrick CJ.
    Wild-Type JAK2 Secondary Acute Erythroleukemia Developing after JAK2-V617F-Mutated Primary Myelofibrosis
    Acta Haematologica 2009;122:36-38.
    Imp.-Fact.:1,191
  • Schalk E, Scheinpflug K, Mohren M.
    Capillary blood count analyses in clinical practise: a safe, reliable and valid method.
    J Lab Med 2009;33(5):303-309
  • Koehler M, Bölter A, Lange J, Dogan E, Heine V, Fischer T, Frommer J.
    Krebspatienten brauchen eine individuelles psychologisches Angebot - 2. Magdeburger Psychoonkologisches Kolloquium.
    Ärzteblatt Sachsen-Anhalt 2009; 20 (4): 50-54.

2008

  • Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer C A, Cortes J, Niederwieser D W, Gambacorti C, Stone R M, Goldman J, Fischer T, O'Brien S G, Reiffers J J, Mone M, Krahnke T, Talpaz M, Kantarjian H M .
    Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment.
    Blood 111(3):1039-43, 2008
    Imp.-Fact.:10,432
  • Lipka D B, Hoffmann L S, Heidel F, Markova B, Blum M -C, Breitenbuecher F, Kasper S, Kindler T, Levine R L, Huber C, Fischer T .
    LS104, a non ATP-competitive small molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2-V617F positive cells.
    Mol Cancer Ther 7(5): 1176-1184, 2008.
    Imp.-Fact.:5,003
  • Kasper S, Breitenbuecher F, Kindler T, Heidel F, Lipka D B, Elliot J, Huber C, Fischer T .
    The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukaemia.
    Leuk Res 32(11):1698-707, 2008.
    Imp.-Fact.:2,39
  • Schalk E, Scheinpflug K, Mohren M .
    Correlation of capillary and venous absolute neutrophil counts in adult hematological patients and normal controls.
    Am J Hematol. 2008;83:605
    Imp.-Fact.:1,949
  • Scheinpflug K, Schalk E, Mohren M.
    Staphylococcal Scalded Skin Syndrome in an Adult Patient with T-Lymphoblastic Non- Hodgkin's Lymphoma
    Onkologie 2008;31:616-619
    Imp.-Fact.:1,227
  • Lipka D, Heidel F, Huber C, Fischer T.
    Entwicklung von Tyrosinkinase-Inhibitoren bei hämatologischen Neoplasien. FLT3 und JAK2 als therapeutische Targets.
    Pharm Unserer Zeit. 2008;37(5):394-403.
  • Koehler M, Bölter A, Lange J, Dogan E, Heine V, Frommer J.
    Perspektiven durch Psychoonkologie 2008: Effektivität psychoonkologischer Interventionen.
    Tumorzentrum aktuell 02/2008; 22-27

2007

  • Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A.
    Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.
    Blood 109:4686-92, 2007
    Imp.-Fact.:10,37
  • Graf C, Heidel F, Tenzer S, Radsak M, Solem F, Britten C, Huber C, Fischer T, Wölfel T
    A neoepitope generated by a FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T-cells.
    Blood 109(7):2985-2988, 2007.
    Imp.-Fact.:10,37
  • Deininger M, Cortes J, Paquette R, Park B, Niederwieser D, Stone R, Hochhaus A, Reiffers J, Fischer T, Kantarjian H, Baccarani M, Gambacorti-Passerini C, So C, Krahnke T, Gathmann I, Druker D Smith Brian, Guilhot F .
    The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Cancer 110:1509-19, 2007.
    Imp.-Fact.:4,582
  • Frühauf S, Topaly J, Buss E, Fischer T, Ottmann O, Emmerich B, Müller M, Schuld P, Balleisen L, Hehlmann R, Ho A, Hochaus A .
    Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukaemia in myeloid blast crisis.
    Cancer 109:1543-9, 2007.
    Imp.-Fact.:4,582
  • Heidel F, Cortes J, Rücker F G, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T .
    Results of a multicenter phase II trial for older patients with c-kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and Imatinib (IM).
    Cancer 109(5):907-14, 2007.
    Imp.-Fact.:4,582
  • Heidel F, Lipka D B, von Auer C, Scharrer I and Hess G.
    Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia
    Thromb Haemost. 2007 Feb;97(2):228-33.
    Imp.-Fact.:3,501
  • Kasper S, Kindler T, Breitenbücher F, Sonnenschein S, Böhmer Frank D, Huber C, Fischer T .
    Cross-inhibition of IFN-induced signal transduction by GM-CSF through a block in STAT1- activation.
    J Interferon Cytokine Res 27(11):947-59, 2007.
    Imp.-Fact.:2,472
  • Schalk E, Heim MU, Koenigsmann M, Jentsch-Ullrich K.
    Use of capillary blood count parameters in adults.
    Vox Sang 2007;93:348-353
    Imp.-Fact.:2,111
  • Al-Batran S E, J T Hartmann, Heidel F, J Stoehlmacher, E Wardelmann, C Dechow, M Düx, J R Izbicki, T Kraus, T Fischer, Jäger E .
    Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
    Gastric Cancer 10(3):145-52, 2007.
  • Drescher D, Moehler M, Gockel I, Frerichs K, Müller A, Biesterfeld S, Holtmann M, Mudter J, Wehler T, Fischer T, Junginger T, Galle P R, Schimanski C C .
    Co-expression of tyrosine kinase receptors in gastric adenocarcinoma – a rationale for a new molecular targeting strategy?
    World J Gastroenterol 13(26):3605-9, 2007.
  • Koehler M, Bölter A, Koehler K, Heine V, Koenigsmann M, Frommer J .
    Perspektiven durch Psychoonkologie 2007: Entwicklung und Stand der psychoonkologischen Forschung.
    Tumorzentrum aktuell 02/2007; 18-22.
  • Koehler M, von Toll T, Koenigsmann M, Frommer J.
    Die psychosomatische Betrachtung der Hämatologie/Onkologie.
    MedReview 2007; 1, 17-18

2006

  • Druker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, Deininger M W N, Silver R T, Goldman J M, Stone R M, Cervantes F, Hochhaus A, Powell B L, Gabrilove J L, Rousselot P, Reiffers J, Cornelissen J J, Hughes T, Agis H, Fischer T Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators.
    Five-Year Follow-up of Imatinib Therapy for Newly Diagnosed Chronic Myeloid Leukemia in Chronic-Phase Shows Sustained Responses and High Overall Survival.
    New England Journal of Medicine 355:2408-17, 2006
    Imp.-Fact.:51,296
  • Heidel F, Solem F K, Breitenbuecher F, Lipka D B, Kasper S, Thiede H M, Serve C Brandts H, Roesel J, Giles F, Feldman E, Ehninger G, Schille G J, Nimer S, Stone R M, Kindler T, Cohen P S, Huber C, Fischer T .
    Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia (AML) by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
    Blood 107(1):293-300, 2006.
    Imp.-Fact.:10,37
  • Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K .
    A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
    Clinical Cancer Research 1;12(15):4628-35, 2006.
    Imp.-Fact.:6,177
  • Mahboobi S, Uecker A, Sellmer A, Cénac C, Höcher H, Pongratz H, Eichhorn E, Hufsky H, Trümpler A, Sicker M, F Heidel, Fischer T, Stocking C, Elz S, Böhmer F D, Dove S .
    Novel Bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinases.
    Journal of Medicinal Chemistry 49: 3101-3115, 2006.
    Imp.-Fact.:5,115
  • Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, Maziarz R, Olavarria E, Verdonck L, Schaefer K, Boqué C, Faber E, Nagler A, Pogliani E, Russell N, Volin L, Schanz U, Doelken G, Kiehl M, Fauser A, Druker B, Sureda A, Iacobelli S, Brand R, Krahl R, Lange T, Hochhaus A, Gratwohl A, Kolb H, Niederwieser D, European Blood and Marrow Transplantation Group.
    The effect of prior exposure to imatinib on transplant-related mortality.
    Haematologica. 2006 Apr;91(4):452-9
    Imp.-Fact.:5,032
  • Schalk E, Mohren M, Jentsch-Ullrich K, Dombrowski F, Franke A, Koenigsmann M.
    Zygomycoses in patients with acute leukaemia
    Ann Hematol 2006;85:327-32.
    Imp.-Fact.:2,254
  • Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg J, Siebler J, Weinmann A, Teufel A, Wörns M, Fischer T, Strand S, Lohse A W, Galle P R .
    Histone deacetylase inhibition by valproic acid downregulates c-FLIP and sensitizes hepatoma cells towards CD95- and TRAIL-receptor mediated apoptosis and chemotherapy.
    Oncology Reports 15: 227-230, 2006.
    Imp.-Fact.:1,567
  • Scheinpflug K, Schalk E, Reschke K, Franke A, Mohren M .
    Diabetes insipidus due to herpes encephalitis in a patient with diffuse large cell lymphoma. A case report.
    Exp Clin Endocrinol Diabetes. 2006 Jan;114(1):31-4.
    Imp.-Fact.:1,356
  • Koehler M, Franke A, Koenigsmann M .
    Psycho-Onkologie in der Klinik für Hämatologie und Onkologie der Otto-von-Guericke-Universität Magdeburg.
    Ärzteblatt Sachsen-Anhalt 2006; 17 (7), 16-35.
  • Koehler K, Kreutzmann N, Koenigsmann M, Koehler M, Franke A, Frommer J .
    Normalisierung durch Übernahme der Patientenrolle: Subjektive Krankheitsvorstellungen, Bewältigungsstrategien und Zukunftserwartungen bei Patienten mit akuter Leukämie nach Adaptation an den Klinikalltag.
    Psychotherapie und Sozialwissenschaft 2006; 1, 11-27.
  • Koenigsmann M, Koehler M, Franke A, Frommer J.
    Acute leukaemia in adults: researching the patient’s perspective.
    Leukemia 2006; 20, 206-207.

2005

  • Heß G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Waßmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann A J, Kindler T, Haus U, Geschaidmeier H, Huber C, Fischer T .
    Sustained complete molecular remissions after treatment with Imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia (CML): Results of a prospective phase II open-label multicenter study.
    Journal of Clinical Oncology 23(30):7583-93, 2005
    Imp.-Fact.:11,81
  • Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Berdel W, H -E Reis, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, ldaoud A A, Pawaresch R,.
    Front-line therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisione (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone – results of
    Blood, 106:3725-32, 2005.
    Imp.-Fact.:10,131
  • Choudhary C, Schwable J, Brandts C, Tickenbrock L, Sargin B, Kindler T, T Fischer, Berdel W E, Muller-Tidow C, Serve H .
    AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Blood. 106(1):265-73, 2005.
    Imp.-Fact.:10,131
  • Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer S D, Gratwohl A, Choudhary C, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen P S, Huber C, Fischer T .
    Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
    Blood 105(1):335-40, 2005
    Imp.-Fact.:10,131
  • Schalk E, Mohren M, Koenigsmann M, Buhtz P, Franke A, Jentsch-Ullrich K.
    Metastatic adrenal neuroblastoma in an adult.
    Onkologie 28(2005), Nr. 6-7, S. 353 - 355
    Imp.-Fact.:1,283
  • Kreft A, Büsche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick C J .
    The Incidence of Myelofibrosis in Essential Thrombocythaemia, Polycythaemia vera and Chronic Idiopathic Myelofibrosis: A Retrospective Evaluation of Sequential Bone Marrow Biopsies.
    Acta Haematologica 113(2):137-43, 2005.
    Imp.-Fact.:1,229
  • Schalk E, Franke A, Koenigsmann M.
    Akute myeloische Leukämie mit pulmonaler Manifestation.
    Pneumologie 59(2005), Nr. 9, S. 588 - 591

2004

  • Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick C J, Theobald M, Gschaidmeier H, Huber C, Fischer T .
    The efficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia.
    Blood, 15;103(10):3644-54, 2004
    Imp.-Fact.:9,782
  • Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, Solano C, Simonsson B, Sonnen R, Diehl V, Fischer T, Caballero D, Littlewood T, Noppeney R, Hossfeld D, Jost L, Delabarre F, Marcus R .
    Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double blind, randomized trial.
    Bone Marrow Transplantation 34(11):955-62, 2004.
    Imp.-Fact.:2,101
  • Kreft A, Burg J, Fischer T, Kirkpatrick C J.
    Essential Thrombocythaemia Terminating in Pure Erythroleukaemia
    Am J Hematol 77(2):140-3, 2004.
    Imp.-Fact.:1,701
  • Koenigsmann M, Knauf W, Herold M, Pasold R, Müller G, Eschenburg H, Kahl C, Lakner V, Assmann M, Jentsch-Ullrich K, Mohren M, Bartsch R, Franke A.
    Fludarabine and bendamustine in refractory and relapsed indolent lymphoma : a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO).
    Leuk. Lymphoma 45(2004), Nr. 9, S. 1821 - 1827
    Imp.-Fact.:1,163

2003

  • O’Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen J L, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman J, Talpaz M, Taylor K, Verhoe.
    Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    New England Journal of Medicine 348(11):994-1004; 2003.
    Imp.-Fact.:34,833
  • Kindler T, Breitenbuecher F, Marx A, Gschaidmeier H, Gamm H, Huber C, Fischer T .
    Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
    Blood 101 (8): 2960-2962, 2003.
    Imp.-Fact.:10,12
  • Johnson B E, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski M O, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, T Le Chevalier .
    Phase II Study of Imatinib Mesylate (Glivec®) for Patients with Small Cell Lung Cancer.
    Clinical Cancer Research, 9:5880-5887, 2003.
    Imp.-Fact.:6,511
  • Nowicki M O, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T .
    Chronic myelogenous leukemia molecular signature
    Oncogene, 22:3952-3963, 2003.
    Imp.-Fact.:6,495
  • Müller MC, Gattermann N, Lahaye T, Deininger M W N, Berndt A, Frühauf S, Reckzeh B, Fischer T, Hossfeld D K, Schneller F, Krause S, Nerl C, Sayer H G, Ottmann O G, Waller C, Aulitzky W, Coutre P Le, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U,.
    Dynamics of BCR-ABL mRNA expression in first line therapy of chronic myelogenous leukemia patients with imatinib or interferon-alpha/ara-C.
    Leukemia, 17(12):2392-400, 2003.
    Imp.-Fact.:5,116
  • Olavarria E, Ottmann O G, Deininger M, Clark R E, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T .
    Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Leukemia, 17(9):1707-12, 2003
    Imp.-Fact.:5,116
  • Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T .
    In bcr-abl - positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by STI571 and Ara-C.
    Leukemia, 17:999-1009, 2003.
    Imp.-Fact.:5,116
  • O'Brien S G, Meinhardt P, Peng B, Beck J, Dutreix C, Mehring G, Milosavljev S, Huber C, Capdeville R, Fischer T .
    Effects of Glivec® on pharmacokinetics of simvastatin, a cytochrome 3A4 substrate in patients with Chronic Myeloid Leukemia.
    British Journal of Cancer 89(10):1855-9, 2003.
    Imp.-Fact.:3,894
  • Hess G, Flohr T, Huber C, Derigs H G, Fischer T .
    Safety and feasibility of CHOP/Rituximab induction treatment followed by high dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated indolent B-NHL.
    Bone Marrow Transplantation 31:775-782, 2003
    Imp.-Fact.:2,172
  • Ullmann A J, Hess G, Kolbe K, Friedrich-Freksa A, Meyer R G, Gschaidmeier H, Huber C, Fischer T .
    Current Results on the Use of Imatinib Mesylate in Patients with Relapsed Philadelphia Chromosome Positive Leukemia after Allogeneic or Syngeneic Haematopoietic Stem Cell Transplantation.
    The Keio Journal of Medicine, 52(3):182-8, 2003.

2002

  • Kantarjian H, Sawyers C L, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederweiser D, Stone R, Goldman J, T Fischer, P Cony-Makhoul, Miller C, M Tallman, O’Brien S, Brown R, Schuster M, Gratwohl A, Loughran T, Mandelli F, Saglio G, Ottmann.
    Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
    New England Journal of Medicine 346 (9): 645 – 652, 2002.
    Imp.-Fact.:31,736
  • Talpaz M, Silver R T, Druker B, Goldman J M, Gambacorti-Passerini C, Guilhot F, Schiffer C A, Fischer T, Niederweiser D, O’Brien S G, Hochhaus A, Ottmann O G, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon F X, Fernandes-Reese S, Gathmann I, Capdeville R.
    Glivec® (imatinib mesylate) Induces Durable Hematologic, Cytogenetic Responses in Patients with Accelerated Phase Chronic Myeloid Leukemia: Results of a Phase II Study.
    Blood 99: 1928 –1937, 2002.
    Imp.-Fact.:9,631
  • Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C, Ottmann O G, Schiffer C A, Talpaz M, Guilhot F, Deininger M W N, Fischer T, O’Brien S G, Stone R, Gambacorti-Passerini C, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Morra E, Larso.
    Glivec® (imatinib mesylate) Induces Hematologic, Cytogenetic Responses in Patients with Chronic Myeloid Leukemia in Myeloid Blast Crisis: Results of a Phase II Study.
    Blood 99: 3530-9, 2002.
    Imp.-Fact.:9,631
  • Ottmann O G, Druker B J, Sawyers C L, Goldman J M, Mahon F X, Silver R T, Tura S, Fischer T, Deininger M, Schiffer C A, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O’Brien S G .
    Glivec® (imatinib mesylate) Induces Hematologic, Cytogenetic Responses in Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Leukemias: Results of a Phase II Study.
    Blood 100: 1965-1971, 2002.
    Imp.-Fact.:9,631
  • Fischer T, Reifenrath C, Hess G, Corsetti M T, Kreil S, Beck J, Meinhardt P, Beltrami G, Schuch B, Gschaidmeier H, Hehlmann R, Hochhaus A, Carella A, Huber C.
    Safety and efficacy of STI-571 (GlivecTM) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation.
    Leukemia 16:1220-1228, 2002.
    Imp.-Fact.:4,693

Letzte Änderung: 09.10.2019 - Ansprechpartner:

Sie können eine Nachricht versenden an: Webmaster
Sicherheitsabfrage:
Captcha
 
Lösung: